Page 5 - Norgine Annual Report 2017
P. 5


 In 2017, Norgine continued its long track record of growth reaching   Norgine opened its new headquarters in the heart of Amsterdam’s business district, at Cross Towers, Antonio
 €345 million net product sales, up 17 per cent. The revenue   Vivaldistraat 150, 1083 HP Amsterdam, Netherlands – a key base to expand its European business, ensure attraction
 increase was due to both the acquisition of Merus Labs International   and retention of talent from across Europe.
 Inc. (“Merus”) and organic growth from Norgine’s key products.
            Norgine has a direct presence in 12 European countries, as well as Australia and New Zealand. Norgine employs
 Products   over 1,000 people, with around 380 in manufacturing and supply, 470 in commercial activities, and 160 in development,
            medical and regulatory, with the remainder employed in global shared services, general and administrative functions.
 Norgine received the European approval for PLENVU and launched
 it in the UK. PLENVU is the only 1-litre PEG bowel preparation for   Norgine does not over-rely on any single country and operates an adaptable infrastructure that allows commercialisation
 cleansing of the colon prior to any procedure requiring a clean bowel.  of new products.

            Norgine is a fully integrated pharmaceutical business, with manufacturing sites in Hengoed, Wales and Dreux, France,
    Growth strategy  third party supply networks and significant product development capabilities, in addition to its sales and marketing

 Norgine accelerated its growth strategy with the acquisition of Merus   infrastructure.
 Labs International Inc. for C$342m. As a result of the transaction                           Over
 Norgine acquired a product portfolio of 12 established products,                        OVER
 SALAGEN  and ESTRADERM  which are sold across Europe and
 other selected markets. Norgine leveraged its significant operating
 infrastructure across Europe to more effectively support these products
 while ensuring that the highest standards of quality are maintained.                    STAFF
 Patients                                                                                  Million
 Norgine’s products were used by over 15 million patients.
 Over the years, Norgine has established relationships with key
 opinion leaders, professional organisations and health services to
 help navigate complex systems and ensure that patients gain access
 to its products. Norgine works together with healthcare professionals,
 organisations and patient groups towards achieving common goals.
 Our objective is to shape policies for the benefit of the patients or to   17
 improve the understanding of complex diseases and treatments.
                GROWTH UP
 3                                                                                                               4
   1   2   3   4   5   6   7   8   9   10